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OBJECTIVEdImpaired awareness of hypoglycemia (IAH) and defective counterregulation
signiﬁcantly increase severe hypoglycemia risk in type 1 diabetes (T1D). We evaluated restora-
tion of IAH/defective counterregulation by a treatment strategy targeted at hypoglycemia avoid-
ance in adults with T1D with IAH (Gold score $4) participating in the U.K.-based multicenter
HypoCOMPaSS randomized controlled trial.
RESEARCH DESIGN ANDMETHODSdEighteen subjects with T1D and IAH (mean6
SD age 50 6 9 years, T1D duration 35 6 10 years, HbA1c 8.1 6 1.0% [65 6 10.9 mmol/mol])
underwent stepped hyperinsulinemic-hypoglycemic clamp studies before and after a 6-month in-
tervention. The intervention comprised the HypoCOMPaSS education tool in all and randomized
allocation, in a 23 2 factorial study design, tomultiple daily insulin analog injections or continuous
subcutaneous insulin infusion therapy and conventional glucose monitoring or real-time continu-
ous glucose monitoring. Symptoms, cognitive function, and counterregulatory hormones were
measured at each glucose plateau (5.0, 3.8, 3.4, 2.8, and 2.4 mmol/L), with each step lasting 40
min with subjects kept blinded to their actual glucose value throughout clamp studies.
RESULTSdAfter intervention, glucose concentrations at which subjects ﬁrst felt hypoglyce-
mic increased (mean 6 SE from 2.6 6 0.1 to 3.1 6 0.2 mmol/L, P = 0.02), and symptom and
plasma metanephrine responses to hypoglycemia were higher (median area under curve for
symptoms, 580 [interquartile range {IQR} 420–780] vs. 710 [460–1,260], P = 0.02; metanephrine,
2,412 [23,026 to 7,279] vs. 5,180 [2771 to 11,513], P = 0.01). Glycemic threshold for
deterioration of cognitive function measured by four-choice reaction time was unchanged,
while the color-word Stroop test showed a degree of adaptation.
CONCLUSIONSdEven in long-standing T1D, IAH and defective counterregulation may be
improved by a clinical strategy aimed at hypoglycemia avoidance.
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Hypoglycemia remains an importantbarrier to achievement of near-normal glucose control in people
with insulin-treated diabetes (1–3). Severe
hypoglycemia (SH), (deﬁned as an event
requiring assistance of another person to
administer carbohydrate, glucagon, or
other resuscitative measures) affects
30–50% of individuals with established
type 1 diabetes (T1D) each year and re-
mains one of themost feared complications,
as it can result in loss of consciousness, sei-
zures or even sudden death (4,5).
In people without diabetes, hypogly-
cemia is prevented by the existence of a
well-coordinated hierarchy of responses
including an early cessation of insulin
secretion. If blood glucose is lowered suf-
ﬁciently (usually under experimental con-
ditions), glucagon secretion increases and a
brisk sympathodrenal response leads to a
rise in epinephrine, symptom generation,
and self-awareness of hypoglycemia. In
established T1D, the ﬁrst and second phys-
iological defenses against hypoglycemia
(decrease in insulin and increase in glucagon
release) are lost, and in many individuals,
epinephrine and other counterregulatory
and symptomatic responses are also di-
minished, leading to the syndromes of “de-
fective glucose counterregulation” and
“impaired awareness of hypoglycemia”
(IAH). IAH affects ~25% of people with
T1D, and it is associated with a sixfold in-
creased risk of SH (6).
Although the pathogenesis is not
entirely clear, it is generally accepted
that hypoglycemia per se is responsible in
part for the syndromes of defective glucose
regulation and IAH, leading to a vicious
cycle of hypoglycemia (7). In a seminal
study by Heller and Cryer, a single episode
of antecedent hypoglycemia caused a gen-
eralized reduction of the neuroendocrine
and symptomatic responses to subsequent
hypoglycemia (8). This ﬁnding has been
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subsequently reproduced in people with-
out diabetes (9,10) and those with T1D
(11) or type 2 diabetes (12). Further sup-
port for this concept derives from recovery
of IAH and defective counterregulation af-
ter eliminating recurrent hypoglycemia in
people with insulinoma (13,14) and in
people with T1D after pancreas (15,16)
and islet cell transplantation (17), as well
as through adherence to treatment proto-
cols aimed at meticulous prevention of hy-
poglycemia (18–21).
Use of continuous subcutaneous in-
sulin infusion (CSII) is reported to reduce
SH (22), but relatively few studies have
compared CSII with modern long-acting
analog insulins, such as insulin glargine as
the basal insulin (23,24). Studies involving
use of real-time continuous glucose moni-
toring (RT-CGM) have also shown reduced
rates of biochemical hypoglycemia (25,26).
In all such studies, improvement of HbA1c
has been the primary outcome, with pre-
vention of SH a secondary (and sometimes
underpowered) end point. No study to
date has evaluated the efﬁcacy of RT-CGM
in combination with CSII or optimized
analog-based multiple daily injections
(MDIs) with the primary objective of re-
versing IAH. A recent study in adolescents
with relatively short duration of T1D
(5.2 6 1.4 years) showed improved epi-
nephrine responses after 4-week use of
RT-CGM with preset low alarms at 6
mmol/L and advice to institute standard
hypoglycemia treatment for blood glucose
levels ,6 mmol/L (27).
The HypoCOMPaSS (Comparison of
Optimised MDI versus Pumps with or
without Sensors in Severe Hypoglycemia)
trial (28) is a U.K.-based, prospective,
multicenter, randomized controlled trial
(RCT) with the primary aim of comparing
the ability to avoid hypoglycemia and re-
versal of IAH using either optimized sub-
cutaneous insulin analog regimen (MDI)
or insulin pump therapy (CSII) with or
without adjunctive RT-CGM in a 2 3 2
factorial design. The primary outcome of
the main HypoCOMPaSS study was the
difference in hypoglycemia awareness de-
termined by Gold score (6) between study
interventions at 24 weeks. All eligible trial
participants were invited to participate in
optional hyperinsulinemic-hypoglycemic
clamp substudies before and after the trial
intervention, with the aim of objectively
demonstrating reversibility of IAH and
counterregulatory responses during con-
trolled hypoglycemic challenge. The pri-
mary outcome for the clamp substudy
was the glucose concentration at which
participants felt hypoglycemic during pro-
gressive hypoglycemia. Here, we describe
the results from those who participated in
paired clamp studies before and 24 weeks
after the study intervention.
RESEARCH DESIGN AND
METHODSdThe full HypoCOMPaSS
trial protocol (including details of the
hyperinsulinemic-hypoglycemic clamp
substudy) has previously been published
(28), but key details are summarized here.
The study protocol, participant information
sheets, and consent forms were approved
by an independent research ethics commit-
tee, and the study was carried out in accor-
dance with the Declaration of Helsinki.
Written informed consent was obtained
from each participant for the main trial,
and separate written consent was obtained
for the optional clamp study described here.
Between July 2010 and June 2011, 96
adults were recruited to the main
HypoCOMPaSS trial from ﬁve U.K. ter-
tiary referral and academic hypoglycemia/
CSII centers. Four of the ﬁve centers
participated in the optional clamp study:
Addenbrooke’s Hospital, Cambridge;
Newcastle Diabetes Centre, Newcastle
upon Tyne; and Derriford Hospital, Ply-
mouth, and Shefﬁeld Teaching Hospitals,
Shefﬁeld.
Key inclusion criteria for the main
HypoCOMPaSS trial participationwere as
follows: 1) age 18–74 years inclusive, 2)
T1D according to World Health Organi-
zation criteria, 3) serum C-peptide ,50
pmol/L with simultaneous exclusion of
biochemical hypoglycemia (glucose
,4.0 mmol/L), and 4) IAH conﬁrmed
by a Gold score (6) of$4 with or without
history of SH in the preceding 12 months
(as deﬁned by the American Diabetes As-
sociation [29]). Key exclusion criteria
comprised any condition precluding in-
formed consent, unwillingness to under-
take intensive insulin therapy and use
study devices, and history of intolerance
to insulin glargine. Additional exclusion
criteria were applied to the optional step-
ped hyperinsulinemic-hypoglycemic
clamp studies as follows: age .60 years,
history of epilepsy (seizures not primarily
induced by hypoglycemia), and known
ischemic heart disease or other signiﬁcant
disease that in the judgment of the inves-
tigators would increase the risks associ-
ated with taking part in the substudy.
HypoCOMPaSS study intervention
After a 4-week run-in period, participants
were randomized to one of four treatment
arms: MDI with conventional self-
monitoring of blood glucose (SMBG),
MDI with SMBG and RT-CGM, CSII with
SMBG, andCSII with SMBG and RT-CGM.
The primary goal of insulin dose titra-
tion throughout the 24-week RCT period
was the absolute avoidance of all glucose
levels,4 mmol/L as determined by CGM
and SMBG. Participants were advised to
treat all glucose levels ,4 mmol/L with
15 g glucose with repeat SMBG every
15 min until glucose .4 mmol/L and to
consider prospective insulin dose reduc-
tion. All participants received a focused
individualized education session (“My
HypoCOMPaSS” tool) at the start of the
24-week RCT period aimed at avoidance
and early detection of all blood glucose
levels ,4 mmol/L with the goal of pre-
venting progression to signiﬁcant hy-
poglycemia while maintaining overall
glycemic control. Further details about
the educational tool and follow-up of par-
ticipants during the 6months intervention
are provided in the Supplementary Data.
Importantly, there was no difference in the
clinical contact time or follow-up between
treatment groups (28).
Clamp study procedures
Clamp studies were conducted in a ded-
icated clinical research facility within re-
spective institutions before and after the
24-week HypoCOMPaSS trial interven-
tion. Participants were ﬁtted with a retro-
spective CGM sensor (Medtronic iPro;
Minimed) to be worn for 5–7 days pre-
ceding the study day. This was downloa-
ded on the morning of the clamp study to
determine whether any antecedent bio-
chemical hypoglycemia occurred over
the 24-h period prior to the clamp. Stud-
ies were rescheduled after repeat CGM
proﬁle if biochemical hypoglycemia (#3
mmol/L) was detected over the preceding
24 h. All participants were advised to fast
from 10:00 P.M. the night before and to
avoid caffeine for 24 h before the study.
Participants were admitted to the
clinical research facility at 7:00 A.M. on
the day of their clamp studies. On arrival,
an intravenous cannula was inserted in
the antecubital vein of the nondominant
arm and blood glucose was stabilized us-
ing sliding-scale Actrapid insulin (Novo
Nordisk, Baegsvard, Denmark) insulin in-
fusion aiming initially for blood glucose
6.0–7.0 mmol/L and then 5.0–6.0 mmol/L
between 10:30 A.M. and 11:00 A.M. for
clamp initiation.
A second retrograde cannula was in-
serted into a vein on the dorsum of the
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nondominant hand, which was heated to
50–608C to arterialize venous blood. Dur-
ing this period of stabilization, participants
practiced cognitive function tests demon-
strated to be sensitive to hypoglycemia:
four-choice reaction time (19,30,31) and
Stroop (32,33) tests. At the start of the
clamp, a primed infusion of 60 mU/m2/
min soluble human Actrapid insulin in a
4% solution of autologous blood in 0.9%
sodium chloride was started via the non-
dominant antecubital vein catheter. In par-
allel, the rate of infusion of 20% dextrose
was adjusted as needed, aiming to stabilize
plasma glucose at 5.0 mmol/L at 40 min
followed by sequential lowering to 3.8
mmol/L, 3.4 mmol/L, 2.8 mmol/L, and
2.4 mmol/L in 40-min steps. Samples for
plasma glucose were obtained every 5 min
and analyzed in real time. Participants re-
mained blinded to their real-time glucose
levels throughout the study.
At the end of each clamp stage,
participants completed a previously vali-
dated questionnaire (Edinburgh Hypo-
glycemia Score) (34) consisting of 11
items requiring rating of four autonomic
symptoms (pounding heart, shaking/
tremor, hunger, and sweating) and ﬁve
neuroglycopenic symptoms (drowsiness,
difﬁculty speaking, clumsiness/incoordi-
nation, odd behavior, and confusion).We
omitted the two nonspeciﬁc symptoms
(nausea and headache) from our analysis.
Each item was scored from 1 (absent) to 7
(maximal) and for ease of interpretation
converted to a scale of 0–6with aminimum-
maximum possible score range of 0–54.
The symptom questionnaire was followed
by the four-choice reaction-time test and
the Stroop test.
Additional blood samples were taken
at regular intervals for the later measure-
ment of insulin, metanephrine, growth
hormone, glucagon, and cortisol. Heart
rate and blood pressure were recorded
every 20 min.
Analytical methods
Arterialized plasma glucose was analyzed
in real time using Yellow Springs analyzer
(YSI STAT Plus, Farnborough, U.K.)
(intra-assay coefﬁcient of variation [CV]
1.5% and interassay CV 2.8%) Plasma
insulin was measured by ELISA (Dako,
Glostrup, Denmark) (intra-assay CV
1.8% and interassay CV 7.8%). Glucagon
was measured by ELISA (Alpco Diagnos-
tics) (intra-assay CV 1.6% and interassay
CV 2.4%). Cortisol levels were measured
using a two-step sandwich immunoassay
(Roche Modular E-170 platform, Elecsys
cortisol reagents) (intra-assay CV 1.4%
[based on a mean value of 593 nmol/L]
and interassay CV 4.7% [based on a mean
value of 535 nmol/L]). Plasma meta-
nephrine (separate from normetanephr-
ine) was measured using ELISA (Alpco
Diagnostics) (intra-assay CV 12% [based
on a mean value of 652 pmol/L] and
interassay CV 12.2% [based on a mean
value of 350 pmol/L]). Growth hormone
was measured using ELISA (Alpco Diag-
nostics) (intra-assay CV 1.4% and inter-
assay CV 4.5%). All samples were
measured in a single central laboratory
in the same batch.
Data and statistical analysis
Glucose thresholds for the onset of symp-
toms, counterregulatory hormone re-
sponses, and impairment of cognitive
function were determined according to
previously published protocols (19,
30,35,36). Brieﬂy, glucose thresholds for
onset of hormone responses were deﬁned
as the time of onset of a sustained ($2
successive time points) increase in hor-
mone concentrations $2 SDs above the
mean of the ﬁve baseline measurements
for that hormone. Thresholds for an in-
crease in total, autonomic, and neurogly-
copenic symptoms were determined as
the time at which the symptoms score in-
creased $2 over baseline on $2 succes-
sive time points. Where no deﬁned
changed occurred, the lowest measured
glucose level during the respective clamp
was used as the threshold for that individ-
ual in keeping with published literature.
Incremental areas under the curve for
symptoms were calculated using incre-
mental symptom scores (subtracting the
symptom score at the end of stage 1 of
the clamp from the scores obtained in
stages 2–5). Incremental areas under the
curve for hormones were calculated by
subtracting the mean hormone levels
achieved during euglycemia (ﬁrst 40
min of the clamp) from subsequent hor-
mone levels during the rest of the clamp.
For hormones, single missing values were
replaced with linear interpolation and the
trapezoidal rule was used for calculation
of the area under curve. For the four-
choice reaction time, glucose thresholds
were determined as the plasma glucose
level when the reaction time ﬁrst excee-
ded twice the CV of the stable baseline
measurements. For Stroop tests, glucose
thresholds were determined as the plasma
glucose level where performance ﬁrst de-
teriorated $2 SDs below the mean base-
line performance.
Data are presented as mean (SE) or
median (interquartile range) unless stated
otherwise. Normally distributed data/
parameters were compared using paired-
samples t tests, while non–normally
distributed data/parameters were com-
pared using the Wilcoxon signed rank
test. Statistical analyses were conducted
using SPSS, version 19 (IBM Software,
Hampshire, U.K.), and P, 0.05 was con-
sidered statistically signiﬁcant.
RESULTS
Study participants
In total, 30 participants consented to the
baseline clamp study, and 27 participants
consented to the post-RCT clamp study.
Stepped hypoglycemic clamp studies
were successfully completed in 25 partic-
ipants at baseline and 22 participants
post-RCT. The most common reason for
premature clamp termination was difﬁ-
culty obtaining arterialized blood from
the retrograde cannula. One clamp study
was prematurely terminated owing to
transient hypotension. Results presented
in this report refer to the 18 participants
(mean 6 SD age 50 6 9 years, T1D du-
ration 35 6 10 years, and HbA1c 8.1 6
1.0% [65 6 10.9 mmol/mol]) who com-
pleted paired baseline and post-RCT
clamp studies. Detailed demographic
and other baseline parameters for the
paired clamp cohort as well as nonclamp
HypoCOMPaSS trial participants are
summarized in Supplementary Table 1.
The participants undergoing paired
clamp studies had signiﬁcantly longer du-
ration of diabetes, earlier onset of disease,
and lower BMI compared with other
HypoCOMPaSS participants. Baseline
HbA1c and Gold score were comparable
between two groups.
Treatment allocations and effects
on glycemic control and hypoglycemia
Of the 18 participants who completed
paired clamp studies, 9 were randomized
to CSII and 9 toMDI, with 11 participants
randomized to conventional monitoring
and 7 subjects to RT-CGM [2 3 2 study
design]). Changes in monthly HbA1c and
percentage of time spent below 3.0mmol/L
during monthly blinded CGM for partic-
ipants undergoing paired clamp studies
are shown in Fig. 1A. Compared with
baseline, the percentage of time spent in
biochemical hypoglycemia (blood glu-
cose ,3.0 mmol/L [54 mg/dL]) was re-
duced by ~65% from baseline to study
care.diabetesjournals.org DIABETES CARE, VOLUME 36, DECEMBER 2013 4065
Leelarathna and Associates
end (4.5 6 0.9% vs. 1.6 6 0.5%, P =
0.015). Further, the percentage of time
spent with blood glucose ,3.9 mmol/L
(70 mg/dL) was reduced by ~50% from
baseline to study end (11.3 6 2.1% vs.
5.66 1.0%, P = 0.025). Importantly, this
was achieved without an overall deterio-
ration in glycemic control as measured by
HbA1c (baseline vs. 24 weeks: 8.1 6
0.2% vs. 8.2 6 0.2% or 65 mmol/mol
vs. 66 mmol/mol, P = 0.66). Compared
with the previous 6 months, annualized
SH rates were signiﬁcantly lower during
the 6-month study intervention: 4 (inter-
quartile range 0–7) vs. 0 (0–0), P = 0.001.
Compared with baseline, post-RCT Gold
scores were signiﬁcantly lower (baseline
vs. 24 weeks: 5.26 0.2 vs. 4.36 0.4, P =
0.009), with 7 of 18 participants showing
reversal (Gold score ,4 at 24 weeks)
and a further 5 of 18 showing an im-
provement in IAH.
As shown in Fig. 1B and C, overall
time spent in hypoglycemia (blood glu-
cose ,3.0 mmol/L [54 mg/dL]) was not
statistically different with CSII and
RTCGM compared with MDI and SMBG
(mean6 SE area under the curve, CSII vs.
MDI 640 6 191 vs.852 6 219, P = 0.47,
and RTCGM vs. SMBG 658 6 223 vs.
797 6 193, P = 0.64).
Results from clamp studies
Plasma glucose levels and dextrose in-
fusion rates during baseline and post-
RCT clamp studies are shown in Fig. 2A
and B. Mean starting glucose level of the
post-RCT clamps was slightly higher than
in the baseline clamps (6.0 6 0.3 vs.
7.0 6 0.4 mmol/L), but by the end of
euglycemic phase (.40 min) glucose lev-
els were comparable (4.76 0.2 vs. 5.06
0.1 mmol/L). Participants achieved simi-
lar glucose levels during the hypoglyce-
mic phase of the clamp studies (.80 to
Figure 1dA: Time spent ,3.0 mmol/L (%)
(C) during monthly blinded continuous glu-
cose monitoring and HbA1c (%) (▫) during the
study intervention for the whole clamp cohort
(N = 18). Data shown are mean6 SEM. (M 0,
baseline, M 1 toM 6, end of each study month.)
B: Time spent ,3.0 mmol/L (%) during
monthly blinded continuous glucose monitor-
ing for MDI (N = 9) (C) and CSII (N = 9) (▫)
groups. C: Time spent ,3.0 mmol/L (%) dur-
ing monthly blinded continuous glucose mon-
itoring for non–RT-CGM (N = 11) (C) and
RT-CGM (N = 7) (▫) groups.
Figure 2dA: Plasma glucose in baseline and post-RCT clamp studies for the whole clamp cohort
(N = 18). B: Dextrose infusion rates in baseline and post-RCT studies for the whole clamp cohort
(N = 18).
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.200 min). There was a tendency for the
amount of dextrose required to maintain
plasma glucose at the desired level to be
lower during the ﬁnal stage of the post-
intervention clamp (Supplementary Fig.
1B) (.160 to .200 min). During the ﬁ-
nal 20 min of studies, mean dextrose in-
fusion rates were 4.8 6 1.9 vs. 4.0 6 1.4
mg/kg/min, P = 0.058, baseline vs. post-
RCT. Importantly, steady state plasma in-
sulin levels were comparable between
baseline and post-RCT clamps (data not
shown).
Self-awareness of hypoglycemia
The plasma glucose concentration at
which subjects ﬁrst felt hypoglycemic
(answer to the question, “Do you feel hy-
poglycemic?”) increased from 2.6 6 0.1
mmol/L at baseline to 3.1 6 0.2 mmol/L
post-RCT (P = 0.017).
Symptom scores
As expected from the study population,
questionnaire symptom scores were low
during baseline clamp studies (Supple-
mentary Fig. 1). During post-RCT clamp
studies, symptom scores were higher
throughout, with a greater increment dur-
ing the ﬁnal stage (160–200 min [Supple-
mentary Fig. 1A and B for autonomic and
neuroglycopenic symptoms]). Although
thresholds for increase in symptom scores
were similar, the total area under the
curve values for total, autonomic, and
neuroglycopenic symptoms were higher
during the postintervention clamp stud-
ies (Table 1), but the incremental area un-
der the curve was only increased
signiﬁcantly for autonomic symptoms.
Hormones
Plasma metanephrine, cortisol, and
growth hormone levels rose with pro-
gressive hypoglycemia, with higher mean
levels during post-RCT studies (Supple-
mentary Tables 2 and 3), but statistical
signiﬁcance was only achieved for plasma
metanephrine response (Table 1). As ex-
pected in this group with long-standing
T1D, glucagon showed no response to
hypoglycemia. Incremental plasma hor-
mone levels during baseline and post-
RCT clamp studies are shown in Fig. 3.
Area under the curve values for incremen-
tal hormone levels and glucose thresholds
for initiation of hormone responses are
shown in Table 1.
Baseline and post-RCT response by
RCT intervention
Symptom and hormonal responses to
hypoglycemia stratiﬁed according to the
2 3 2 study design are shown in Supple-
mentary Tables 4 and 5. Compared with
baseline, participants in the CSII arm
achieved higher symptom and hormonal
responses after the trial intervention,
reaching statistical signiﬁcance in several
key parameters including the threshold
for metanephrine secretion. In contrast,
participants using MDI showed smaller
responses, which were non–statistically
signiﬁcant compared with baseline. Simi-
larly, those who were allocated to RT-CGM
showed similar trends, but statistically sig-
niﬁcant improvements were only seen in
total symptoms and the threshold for
secretion of metanephrine, while no sta-
tistical signiﬁcance was seen in the Non–
RT-CGM group.
Direct head-to-head comparison of
change in subjective awareness, symptoms,
and hormonal responses from baseline to
post-RCT are shown in Supplementary
Table 6. There was a tendency for the
CSII group to show more pronounced
improvements compared with the MDI
group, but no statistical signiﬁcance was
achieved.
Cognitive function tests
We did not observe any statistically sig-
niﬁcant differences in cognitive function
test performance at the start of the base-
line and post-RCT clamp studies. Perfor-
mance in both four-choice reaction-time
Stroop tests deteriorated signiﬁcantly
with progressive hypoglycemia (Supple-
mentary Tables 7–10). Thresholds for de-
terioration of cognitive function were
similar in baseline and post-RCT clamps
as measured by four-choice reaction time
(2.7 6 0.1 vs. 2.7 6 0.1 mmol/L, P =
0.90), Stroop black and white reading
(2.8 6 0.1 vs. 2.9 6 0.2 mmol/L, P =
0.47), and color “X” components (2.6 6
0.1 vs. 2.8 6 0.1 mmol/L, P = 0.30). In
contrast, the plasma glucose threshold
for deterioration of cognitive function
based on the color word interference
component of the Stroop test changed
Table 1dSymptom and hormonal responses to clamped hypoglycemia in clamp substudy
participants (N = 18)
Baseline Post-RCT P
Glucose level: subject felt
low (mmol/L)
2.6 6 0.1 3.1 6 0.2 0.02
Symptoms AUC
Total 500 (365–685) 650 (365–1,285) 0.02
Autonomic 210 (60–450) 290 (60–790) 0.05
Neuroglycopenic 210 (105–395) 350 (135–640) 0.02
Symptoms AUC (incremental)†
Total 270 (210 to 425) 230 (15–470) 0.52
Autonomic 0 (270 to 170) 30 (210 to 2330) 0.04
Neuroglycopenic 190 (55–395) 230 (220 to 325) 0.31
Glucose thresholds (mmol/L)
for onset of symptoms
Total 2.6 (2.4–3.5) 2.9 (2.4–3.3) 0.83
Autonomic 2.4 (2.3–2.6) 2.5 (2.3–2.9) 0.79
Neuroglycopenic 2.5 (2.3–3.3) 2.8 (2.4–3.4) 0.21
Hormones AUC (incremental)‡
Metanephrines 2,412 (23,026 to 7,279) 5,180 (2771 to 11,513) 0.02
Cortisol 2,321 (28,751 to 14,711) 4,181 (2560 to 16,667) 0.18
GH 1,268 (237 to 1,768) 550 (233–1,297) 0.75
Glucagon 2102 (24,666 to 21,749) 2632 (23,491 to 2845) 0.84
Glucose thresholds
Metanephrines 2.4 (2.3–2.5) 2.7 (2.3–3.2) 0.03
Cortisol 2.6 (2.4–3.2) 2.6 (2.4–3.0) 0.89
GH 3.2 (2.4–3.8) 3.2 (2.7–3.6) 0.98
Glucagon NA NA
Data shown are median (interquartile range) and analyzed by Wilcoxon signed rank test. Boldface indicates
statistical signiﬁcance. AUC, area under the curve calculated using the trapezoid rule after linear interpolation
of any missing data. †Incremental area under the curve for symptoms was calculated after subtracting the
symptom score at the end of stage 1 (140min) from stages 2–5 (180 to1200min). ‡Incremental area under
the curve for hormones was calculated after subtracting the mean hormone level during euglycemia from
subsequent hormone levels during hypoglycemia (stages 2–5).
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from 2.6 6 0.1 mmol/L at baseline to
3.06 0.2mmol/L in the post-RCT clamp
(P = 0.045).
CONCLUSIONSdWe used insulin
clamp studies to create controlled repro-
ducible hypoglycemic challenges to mea-
sure objectively responses to hypoglycemia
in a subset of participants within the
HypoCOMPaSS trial. Our results show
that IAH may be improved, even in adults
with long-standing T1D using a treatment
strategy avoiding hypoglycemia without
worsening overall glycemic control. During
post-RCT clamp studies, most participants
had higher symptom scores despite an
equal hypoglycemic stimulus to baseline
and ﬁrst felt hypoglycemic at a higher
blood glucose value. Both the concentra-
tion and the threshold for secretion of
plasma metanephrine (metabolite of the
key counterregulatory hormone epi-
nephrine) were signiﬁcantly improved
during post-RCT clamps.
The degree of reversibility of IAH
(symptom scores and glucose threshold
for onset of symptoms) demonstrated in
our study was less than in previous studies
documenting the reversal of IAH where
researchers were able to achieve near-
complete avoidance of hypoglycemia (18–
20,37). To achieve this, previous reports
in small single-center experimental medi-
cine studies without an RCT setting
necessitated a highly focused approach
with signiﬁcant time and resource invest-
ment by the study team. For example, in
the study by Cranston et al. (19) there was
an absolute requirement for participants to
consume snacks betweenmeals and at bed-
time together with reduction in insulin
doses. They were contacted weekly for in-
sulin dose adjustment, and the second
clamp was only performed after 3 weeks
of absolute avoidance of hypoglycemia.
Similarly, in the study by Fanelli et al.
(20) participants were telephoned up to
four times daily. In the study by Fritsche
et al. (37), preprandial target glucose was
raised from 5.6 to 8.3 mmol/L and target
bedtime glucose was increased from 5.6 to
10mmol/L. In contrast, we aimed to main-
tain tight glycemic targets throughout the
study, did not require participants to make
any signiﬁcant changes to lifestyle, and did
not ask them to take regular snacks be-
tweenmeals or at bedtime.Within the cur-
rent HypoCOMPaSS multicenter trial, we
were not able to eliminate completely hy-
poglycemia in this group with long-
standing T1D and IAH. Based on blinded
CGM data, signiﬁcant biochemical
hypoglycemia (,3.0 mmol/L) was re-
duced by .60% over the ﬁrst 4 weeks
and maintained throughout the study
period in the whole cohort. Although sig-
niﬁcantly lower compared with baseline,
this ongoing biochemical hypoglycemia
(compared with absolute avoidance) may
explain the lesser degree of reversibility in
our study. In addition, it is important to
note that our study participants had long
duration of diabetes (mean duration of
~35 years). This is considerably longer
than the previous clamp studies, which
demonstrated reversibility of IAH (18–20)
In this study, we did not demonstrate a
deﬁnite advantage for one treatment mo-
dality over another. The trend for more
marked improvements in awareness and
responses to hypoglycemia in the CSII
group compared with MDI (also for
RT-CGM for some parameters) failed to
reach statistical signiﬁcance. It is also worth
noting that participants in the CSII arm
had lower symptom area under the curve
and lower incremental metanephrine area
under the curve than did the MDI group
during baseline clamp. Our data suggest
that even in long-standing T1D, defenses
against hypoglycemia may be improved
by clinical strategies aimed at minimizing
ongoing biochemical hypoglycemia (includ-
ing close professional support, education,
and the judicious use of CSII or RT-CGM
where appropriate).
We found no difference in the thresh-
old for cognitive deterioration based on
four-choice reaction time. This observa-
tion is consistent with previous studies
(19,30) and supports the notion that
there is no adaptation of the glucose level
at which cognitive dysfunction occurs
(30). However, the most difﬁcult compo-
nent of the Stroop test (color-word inter-
ference) did show change in the threshold
for impairment from 2.66 0.1 mmol/L at
baseline to 3.06 0.2 mmol/L in the post-
RCT clamp (P = 0.045). Several previous
studies, which have used a battery of cog-
nitive function tests, have also reported
such changes in glycemic thresholds
Figure 3dIncremental plasma hormone levels during baseline and post-RCT clamp studies for
the whole clamp cohort (N = 18). Data shown are mean 6 SE.
4068 DIABETES CARE, VOLUME 36, DECEMBER 2013 care.diabetesjournals.org
Improving hypoglycemia awareness in T1D
(13,18,20) (downward shift in partici-
pants with IAH and subsequent upward
shift during reversal of unawareness). It is
possible that different cognitive function
tests relate to different areas in the brain
and some tests (and brain areas) are more
sensitive to hypoglycemia than others and
may also have different levels of adapta-
tion to recurrent hypoglycemia. Alterna-
tively, it is possible that performance of
some cognitive function tests is affected
by the distraction caused by recovery of
symptoms during post-RCT clamps.
Our study has a number of strengths.
It is the ﬁrst RCT clamp study series to our
knowledge to examine modern treatment
strategies including the use of contempo-
rary CSII and RT-CGM in a group of sub-
jects with long-standing T1D and IAH.
Further, clinically meaningful improve-
ments have been conﬁrmed by insulin
clamp studies for the ﬁrst time within a
multicenter RCT involving interventions
that might be incorporated into routine
clinical practice. Limitations of our sub-
study include the lack of a control group,
which did not undergo any intervention;
the relative lack of power to establish the
superiority of a single treatment; and the
potential for contamination in a single
center and measurement of plasma meta-
nephrine rather than epinephrine. We col-
lected samples for measurement of plasma
epinephrine, but technical failures with
assays prevented this. Since .90% of cir-
culating metanephrine is produced within
the adrenal medulla by the conversion of
epinephrine to metanephrine by catechol-
O-methyl transferase (38), plasma meta-
nephrine level may act as a surrogate
marker of epinephrine production. How-
ever, since the conversion of epinephrine
to metanephrine takes some time, use of
metanephrine may have underestimated
the onset and magnitude of catecholamine
response. It is also worth noting that exper-
imental hypoglycemia induced during
clamp studies may not be totally represen-
tative of hypoglycemia under real-world
conditions, but the objective of this sub-
study was to compare responses before
and after a treatment strategy using a repro-
ducible hypoglycemic challenge.
In conclusion, results from the clamp
substudy of the HypoCOMPaSS trial
show that even in adults with long-standing
diabetes, meaningful recovery of subjec-
tive awareness and counterregulatory re-
sponses to hypoglycemia can be achieved
using a management strategy aimed at
avoidance of hypoglycemia without relax-
ation of overall glycemic control. Further
work is underway to identify the baseline
and other characteristics associated with
recovery and nonrecovery of hypoglyce-
mia awareness and counterregulatory re-
sponses in this cohort with long-standing
T1D.
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